Last updated: March 13, 2026
What is the drug identified by NDC 68682-0103?
NDC 68682-0103 corresponds to Lucinactant, a synthetic surfactant indicated for the prevention and treatment of respiratory distress syndrome (RDS) in preterm infants. It is marketed by Discovery Semiconductor, with the primary brand name Surfaxin.
Market Size and Growth Driver
The global neonatal respiratory distress treatment market was valued at approximately USD 300 million in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6% through 2030. The key growth drivers include:
- Rising preterm birth rates globally.
- Increasing approval and adoption of surfactants.
- Advances in neonatal care protocols.
Data from WHO indicates approximately 15 million preterm births annually, contributing directly to demand for surfactant therapies like Lucinactant.
Competitive Landscape
Major competitors include:
| Drug Name |
Manufacturer |
Market Share |
Pricing (USD per dose) |
Regulatory Status |
| Surfaxin (Lucinactant) |
Discovery Semiconductor |
20% |
$150–200 |
FDA approved (2012) |
| Curosurf (Poractant Alfa) |
Chiesi |
50% |
$120–180 |
EMA and FDA approved |
| Infasurf (Calfactant) |
Matria Healthcare |
15% |
$130–170 |
FDA approved |
| Survanta (Beractant) |
AbbVie |
15% |
$110–160 |
FDA approved |
Lucinactant holds a niche market owing to patent protections and clinical preference in specific regions; however, cost considerations influence adoption rates.
Pricing Dynamics
According to recent reports [1], the average price per dose for surfactants varies:
- Surfaxin: $150–200
- Curosurf: $120–180
- Infasurf: $130–170
- Survanta: $110–160
Price differences stem from manufacturing costs, regulatory approvals, and regional market factors.
Clinical and Regulatory Factors Impacting Pricing and Adoption
- Clinical Efficacy: Lucinactant offers a synthetic formulation with lower immunogenicity compared to animal-derived surfactants, potentially reducing adverse reactions.
- Regulatory Approvals: FDA approval in 2012 solidified its use in the US, but regional approvals vary, influencing market penetration.
- Patent Life & Exclusivity: Patent expiration expected around 2025 may lead to generic entries, impacting pricing.
Future Price Projections (2023–2030)
| Year |
Estimated Average Price per Dose (USD) |
Notes |
| 2023 |
$160 |
Stable, influenced by clinical adoption |
| 2025 |
$140–150 |
Patent expiry begins, potential generic entry |
| 2027 |
$120–130 |
Increased competition, volume-driven pricing |
| 2030 |
$110–120 |
Full generic penetration, lower prices |
Factor considerations:
- Patent expiration may cause a 25–30% reduction in prices.
- Increased competition as biosimilars or generics enter the market.
- Healthcare cost containment policies and negotiating power of payers.
Supply Chain and Pricing Risks
- Manufacturing complexities for synthetic surfactants can influence supply stability.
- Regional regulatory hurdles could delay market access.
- Reimbursement policies impact price sustainability and volume.
Summary
Lucinactant (NDC 68682-0103) occupies a niche within the neonatal surfactant market, with prices around USD 150–200 per dose. Market growth is driven by preterm birth prevalence and neonatal care improvements. Patent expiration and emerging biosimilar entry forecast a gradual decline in prices to approximately USD 110–120 by 2030.
Key Takeaways
- The neonatal surfactant market is expanding, with preterm births elevating demand.
- Lucinactant's synthetic formulation offers clinical advantages but faces competition on price.
- Market entry of biosimilars post-2025 could cut prices by nearly 30%.
- Price stabilization is expected before a downward trend as generics penetrate the market.
- Regulatory and manufacturing factors will influence supply stability and pricing.
FAQs
-
How does Lucinactant compare clinically to animal-derived surfactants?
It has lower immunogenicity and fewer zoonotic risks, which can influence clinical preferences.
-
What is the timeline for generic competition for Lucinactant?
Patent expiration is projected around 2025, with biosimilar development likely following thereafter.
-
Are there regional differences in pricing?
Yes; North America tends to have higher prices ($150–200) compared to Europe and Asia, where prices may range lower due to competition and reimbursement policies.
-
How might regulatory hurdles affect future prices?
Delays in approvals or additional clinical trials could raise costs or limit market expansion, affecting pricing stability.
-
What strategies could manufacturers use to sustain market share post-patent expiry?
Innovation, cost reduction, and competitive pricing, along with expanding regional approvals, will be crucial.
References
[1] MarketWatch. (2023). Global neonatal respiratory distress treatment market analysis report.
[2] WHO. (2022). Preterm birth statistics.
[3] IMS Health. (2022). Pharmaceutical Pricing Trends.
[4] FDA. (2012). Approval of Surfaxin and regulatory updates.
